NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases.
The Company’s advanced portfolio of therapeutic candidates target life-threatening and life-limiting diseases in the inflammation, infection and respiratory space.
NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to initiation of phase 3 clinical trials of its portfolio of therapeutic candidates. These first in class molecules have been developed from NovaBiotics’ two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.